Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Immunol Rev. 2016 Jan;269(1):145–161. doi: 10.1111/imr.12344

Fig. 5. Proposed model for SIAE action.

Fig. 5

9-O-acetylation of sialic acid glycans on the BCR complex can be expected to inhibit inhibitory glycan-dependent interactions between CD22 and BCR. SIAE can remove the 9-O-acetyl moieties, thereby allowing CD22-mediated inhibition of BCR signaling. Note that this model is inconsistent with the model of CD22 action depicted in Fig. 4.